Steve Norman from Sustain Commercial Solar Ltd guides us through a smarter approach to sustainability when it comes to powering net zero in housing and healthcare.
Mark Reynolds, Chief Technology Officer at NHS Digital, talks about the unique challenges brought about by the pandemic, and how using data innovatively with the Shielded Patient List and Population Risk Assessment helped to identify and protect some of the most vulnerable in society.
Dr Mark Brookes MBE, Advocacy Lead at Dimensions UK, discusses the implications of the Elections Bill and measures to introduce voter ID on voter participation for people with a learning disability.
Francesca Gargaglia, COO and CBO, Amity, argues that although social media platforms should be responsible for preventing the spread of COVID-19 misinformation, government agencies should build their own communities that build trust and promote well-informed discussions.
A sustainable battery value chain is one of Europe’s weapons to combat climate change, Michael Lippert, Chairman of BEPA - Batteries European Partnership Association argues.
Dr Kristen Kroll from Washington University School of Medicine discusses new approaches for studying autism and other neurodevelopmental disorders by using human cellular models of brain development.
Afshin Attari, Senior Director, Public Sector & Unified Platforms, Exponential-e, explains why CCS frameworks are a flexible & assured route to procure IT services.
The Articulation of Indigenous Peoples of Brazil (APIB) filed a case with the International Criminal Court (ICC), claiming that Brazilian President Bolsonaro has pushed "intentional anti-Indigenous policy" since 2019.
Nick Sacke, Head of IoT Solutions, Comms365, discusses some priority challenges local authorities face & how IoT deployments can be rapidly rolled out & scaled to overcome & exceed such challenges.
Frances Goodrum, Head of External Affairs, Brooke Action for Working Horses and Donkeys, walks us through why we need to protect the invisible enablers of food security in light of COVID-19.
The US Food and Drug Administration (FDA) have approved a third Pfizer dose for people who are immunocompromised - despite the WHO asking countries to wait until 20% were double-vaccinated, globally.
